Parabilis医药
PBLS
22.75
-2.43
-9.65%
Parabilis医药
US · PBLS
#2366 按市值排名
上市于 2026
22.75
-2.43
-9.65%
实时 - 追踪5344个代码 - 心跳于353秒前
· 2026-10-16 20:01
✦ 量化股权信号 计算方式说明
减持
- 机构持股总比例下降了3.7个百分点。
机构持股
- 机构持股比例
- 84.59% -3.69pp
- 机构数量
- 86
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
VC/PE Fund50.86%
Mutual Fund19.91%
Hedge Fund10.43%
Public Company3.40%
Other15.31%
主要股东 截至 2026-07-22
RA Capital Management, L.P.
23.62% · 29.18M 股
FMR
8.33% · 10.29M 股
Arch Venture Partners, L.P.
5.19% · 6.41M 股
venBio LLC
4.26% · 5.27M 股
GV Management Company, LLC
3.98% · 4.92M 股
Nextech Invest Ltd.
3.77% · 4.66M 股
Cormorant Asset Management, LP
3.74% · 4.62M 股
Mwg Management Ltd.
3.70% · 4.57M 股
Regeneron Pharmaceuticals, Inc.
3.37% · 4.17M 股
Artal Group S.A.
2.42% · 2.99M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪33份申报 · 23次买入 · 0次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| RA Capital Management, L.P. | -- | 23.62% |
| Alexis Borisy | Independent Director | 0.09% |
| Edward Fitzgerald | Independent Director | 0.01% |
| Alan Sebulsky | Independent Director | -- |
| Deerfield Management Company, L.P. | -- | -- |
| Richard Klausner | Independent Director | -- |
| Apothecary Capital LLC | -- | -- |
| Mathai Mammen | CEO, President, Treasurer & Chairman | -- |
| Krishna Yeshwant | Independent Director | -- |
| Barbara Weber | Independent Director | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-08-21 | Craig Tendler | Director & Scientific Advisor | Other Derivative Acquisition | +20,294 | $39.36 |
| 2026-08-21 | Craig Tendler | Director & Scientific Advisor | Initial Statement of Beneficial | 0 | -- |
| 2026-07-21 | RA Capital Management, L.P. | -- | Open Market Acquisition | +244,593 | $27.13–30.00 |
| 2026-06-14 | Apothecary Capital LLC | -- | Open Market Acquisition | +17,500 | $26.00–27.67 |
| 2026-06-10 | Edward Fitzgerald | Independent Director | Other Derivative Acquisition | +3,666 | -- |
| 2026-06-10 | Edward Fitzgerald | Independent Director | Other Derivative Acquisition | +5,332 | -- |
| 2026-06-10 | Edward Fitzgerald | Independent Director | Other Derivative Acquisition | +8,111 | -- |
| 2026-06-10 | Edward Fitzgerald | Independent Director | Derivative Exercise and Retained | +14,688 | -- |
| 2026-06-10 | Alexis Borisy | Independent Director | Other Derivative Acquisition | +162,221 | -- |
| 2026-06-10 | Alexis Borisy | Independent Director | Derivative Exercise and Retained | +105,414 | -- |
| 2026-06-10 | Deerfield Management Company, L.P. | -- | Derivative Exercise and Retained | +1,880,704 | -- |
| 2026-06-10 | Apothecary Capital LLC | -- | Private Acquisition | +12,500 | $20.00 |
| 2026-06-10 | RA Capital Management, L.P. | -- | Private Acquisition | +21,188,750 | $20.00 |
| 2026-06-10 | RA Capital Management, L.P. | -- | Derivative Exercise and Retained | +7,744,621 | -- |
| 2026-06-10 | Soleus Capital Management, L.P. | -- | Private Acquisition | +500,000 | $20.00 |
| 2026-06-10 | Soleus Capital Management, L.P. | -- | Derivative Exercise and Retained | +527,070 | $9.48 |
| 2026-06-08 | Edward Fitzgerald | Independent Director | Other Derivative Acquisition | +20,215 | $20.00 |
| 2026-06-08 | Edward Fitzgerald | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-06-08 | Alan Sebulsky | Independent Director | Other Derivative Acquisition | +39,792 | $20.00 |
| 2026-06-08 | Alexis Borisy | Independent Director | Other Derivative Acquisition | +20,215 | $20.00 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 20:01:03 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
Parabilis医药 讨论区 0 条评论